Share on StockTwits

Shares of ZS Pharma (NASDAQ:ZSPH) were the recipient of a significant growth in short interest in August. As of August 15th, there was short interest totalling 680,843 shares, a growth of 24.4% from the July 31st total of 547,249 shares, American Banking and Market News reports. Based on an average daily trading volume, of 55,071 shares, the short-interest ratio is presently 12.4 days. Approximately 8.2% of the shares of the company are short sold.

Several analysts have recently commented on the stock. Analysts at Credit Suisse raised their price target on shares of ZS Pharma from $51.00 to $54.00 in a research note on Tuesday. Finally, analysts at William Blair initiated coverage on shares of ZS Pharma in a research note on Monday, July 14th. They set an “outperform” rating and a $75.00 price target on the stock.

Shares of ZS Pharma (NASDAQ:ZSPH) opened at 39.00 on Thursday. ZS Pharma has a 52 week low of $25.51 and a 52 week high of $43.00. The stock has a 50-day moving average of $31.52 and a 200-day moving average of $30.48. The company’s market cap is $811.9 million.

ZS Pharma (NASDAQ:ZSPH) last announced its earnings results on Thursday, August 14th. The company reported ($4.72) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.66) by $4.06. On average, analysts predict that ZS Pharma will post $-3.95 earnings per share for the current fiscal year.

ZS Pharma, Inc is a biopharmaceutical company focused on the development and commercialization of selective, non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.

Receive News & Ratings for ZS Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZS Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.